Candidiasis vulvovaginal

Vulvovaginal candidiasis. Typical symptoms include vaginal itching and discharge. Clinical characteristics include ... 

Metronidazole (Flagyl) Vulvovaginal Candidiasis 250 mg three times daily for 7 days First-line agent in pregnancy avoid during lactation... 

Explain the underlying pathophysiology of vulvovaginal candidiasis, oropharyngeal candidiasis, esophageal candidiasis, and fungal skin infections. 

Recognize when long-term suppressive therapy is indicated for a patient with vulvovaginal candidiasis. 

O The predominant pathogen associated with vulvovaginal candidiasis is Candida albicans, although a small percentage of cases are caused by Candida glabrata, Candida tropicalis, Candida krusei, and Candida parapsilosis. 

A variety of factors may increase the risk of developing symptomatic vulvovaginal candidiasis, including antibiotic use, diabetes, and immunosuppression. No risk factors are consistently associated with all cases of vulvovaginal candidiasis. 

Asymptomatic vaginal colonization of Candida albicans is not diagnostic of vulvovaginal candidiasis since 10% to 20% of women are asymptomatic carriers of Candida species. Asymptomatic vaginal colonization does not require treatment. 

Selection of antifungal agents to treat uncomplicated vulvovaginal candidiasis is influenced by patient preference,... 

Recurrent vulvovaginal candidiasis, defined as four or more infections per year, requires long-term suppressive therapy for 6 months. 

Vulvovaginal candidiasis (WC), whether symptomatic or asymptomatic, refers to infections in women whose vaginal cultures are positive for Candida species. 

Patients with vulvovaginal candidiasis may present with vulvar and/or vaginal symptoms. Symptoms often develop the week before menses and resolve with the onset of menses. Symptoms include ... 

TABLE 80-1. Possible Risk Factors Associated with Vulvovaginal Candidiasis (VVQ... 

Provide patient education pertaining to vulvovaginal candidiasis and antifungal therapy. 

McCaig LF, McNeil MM. Trends in prescribing for vulvovaginal candidiasis in the United States. Pharmacoepidemiol Drug Saf 2005 14 113-120. 

Redondo-Lopez V, Meriwether C, Schmitt C, Opitz M, Cook R, Sobel JD Vulvovaginal candidiasis complication bacterial vaginosis. Sex TransmDis 1990 17 51—53. 

---